Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England

Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England

Autologous stem‐cell transplantation (ASCT) is standard therapy for relapsed/refractory large B‐cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EJHaem 2024-10, Vol.5 (5), p.992-997
Hauptverfasser: Fox, Christopher P., Townsend, William, Gribben, John G., Menne, Tobias, Kalakonda, Nagesh, Williams, Paula, Toron, Farah, Tyas, Emma, Cooper, Miranda, Rickards, Joshua, Radford, John
Format: Artikel
Sprache:eng
Schlagworte:
Age
ASCT
Chemotherapy
Induction therapy
LBCL
Lymphoma
outcomes
Patients
real‐world evidence
Short Report
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Autologous stem‐cell transplantation (ASCT) is standard therapy for relapsed/refractory large B‐cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression‐free survival (PFS) and event‐free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.
ISSN:2688-6146
2688-6146
DOI:10.1002/jha2.970